Amathus Therapeutics, Merck In Agreement For Neurodegenerative Disease-Targeted TherapiesBenzinga • 03/17/21
European Commission Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)Business Wire • 03/17/21
4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus PackageThe Motley Fool • 03/17/21
Immutep's Lead Candidate To Be Tested In Combination With Keytruda In Second Head & Neck Cancer StudyBenzinga • 03/16/21
Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)Business Wire • 03/16/21
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract CancerPRNewsWire • 03/16/21
Gilead, Merck Hook Up In Long-Anticipated HIV Drug Deal, Stoking SharesInvestors Business Daily • 03/15/21
Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with GileadBusiness Wire • 03/15/21
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIVBusiness Wire • 03/15/21
Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021Business Wire • 03/08/21